EAU 2013 - Programme Book - YouMed

Monday, 18 March
Sponsored Session
17.45 - 19.15 Castration-resistant prostate cancer in 2013: Analysing the good, the
bad and the ugly
Red Hall 2 - Level N1
Symposium
Chairs: K. Miller, Berlin (DE)
Welcome and introduction
K. Miller, Berlin (DE)
Making the most of the multidisciplinary team for castration-resistant prostate cancer (CRPC)
S. Joniau, Leuven (BE)
New treatment options for metastatic CRPC
J. Bellmunt, Barcelona (ES)
Questions & answers
Bone metastases: A defining feature of clinical course in CRPC
K. Miller, Berlin (DE)
Bone-targeted therapy: A new era
K. Fizazi, Villejuif (FR)
Interactive faculty panel discussion
Concluding remarks
K. Miller, Berlin (DE)
Aims and objectives
Target audience
This educational activity is appropriate for urologists, radiation oncologists, clinical oncologists, medical
oncologists, and other healthcare professionals interested in the treatment of patients with castrationresistant
prostate cancer (CRPC). The goal of this educational activity is to improve participants’ ability to
provide optimal medical care for patients with CRPC.
Learning objectives
At the conclusion of this activity, participants should be able to:
• Evaluate strategies for effectively collaborating in a multidisciplinary team when managing patients with
castration-resistant prostate cancer (CRPC)
• Select optimal second-line therapies for patients with docetaxel-resistant CRPC
• Employ best practices when managing bone metastases in men with CRPC
• Integrate novel bone-directed therapies and approaches when treating men with CRPC
Sponsored by PRIME ONCOLOGY
EAU Milan 2013
421
Sponsored Sessions